=> d his

(FILE 'HOME' ENTERED AT 14:59:14 ON 22 DEC 2004)

FILE 'USPATFULL' ENTERED AT 15:05:46 ON 22 DEC 2004
L1 3971 S (PROTEIN OR PEPTIDE OR POLYPEPTIDE) (7A) ((RICH OR ENRICHED O
L2 2 S L1/CLM

FILE 'CAPLUS' ENTERED AT 15:12:22 ON 22 DEC 2004
L3 3 S (PROTEIN OR PEPTIDE OR POLYPEPTIDE) (7A) ((RICH OR ENRICHED O

=> d bib,abs 1-3

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:465526 CAPLUS
DN 125:135004
TI Enhanced metalloadsorption of bacterial cells displaying **poly-His peptides**
AU Sousa, Carolina; Cebolla, Angel; de Lorenzo, Victor
CS Centro Nacional Biotecnologia-CSIC, Campus Cantoblanco, Madrid, 28049, Spain
SO Nature Biotechnology (1996), 14(8), 1017-1020
CODEN: NABIF9; ISSN: 1087-0156
PB Nature Publishing Co.
DT Journal
LA English
AB The properties of Escherichia coli cells, acquired by cell surface presentation of one or two hexahistidine (His) clusters carried by the outer membrane LamB protein, have been examined Strains producing LamB hybrids with the His chains accumulated greater than 11-fold more Cd2+ than E. coli cells **expressing** the protein without the His insert. Furthermore, the hexa-His chains on the cell surface caused cells to adhere reversibly to a Ni2+-containing solid matrix in a metal-dependent fashion. Thus, **expression** of **poly-His peptides** enables bacteria to act as a metalloaffinity adsorbent. These results open up the possibility for biosorption of heavy ions using engineered **microorganisms**.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:498301 CAPLUS
DN 122:308086
TI Fused proteins for preparing vasoactive intestinal polypeptide analogs, method of preparing same and recombinant plasmids and transformant **microorganisms**.
IN Takahashi, Haruo; Kobayashi, Yohei; Nakoshi, Masanao; Mitani, Takahiko; Hirade, Kinya; Sawai, Kiichi
PA Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SO Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 622459	A1	19941102	EP 1994-106392	19940425
	R: BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 06306100	A2	19941101	JP 1993-99313	19930426
PRAI	JP 1993-99313	A	19930426		

AB The invention provides a process for preparing, in large quantities, VIP analogs having potent biol. activity and good stability by utilizing recombinant DNA technol. Thus, a DNA coding for a peptide comprising a leader peptide derived from Sarcophaga lectin and one mol., or a plurality of mols. arranged in tandem, of a **polypeptide** of the general

formula: **His**-Ser-**Asp**-Ala-Val-Phe-Thr-R1-R2-Tyr-Thr-R3-Leu-Arg-Lys-Gln-Leu-Ala-R4-R5-Lys-Tyr-Leu-R6-R7-R8-R9-R10-Met wherein R1 is Asp or Gly, R2 is Asn or Gln, R3 is Arg or Lys, R4 is Val, Ala or Lys, R5 is Lys or Leu, R6 is Asn, Gln or Lys, R7 is Ser, Lys or Ala, R8 is Ile, Ala or Leu, R9 is Leu or Lys and R10 is Asn, Lys or Arg, is inserted into an **expression** plasmid, Escherichia coli is transformed with the resulting recombinant plasmid, and the transformant is cultured to give large quantity **expression** of the above-mentioned polypeptide in the form of a fused protein. Treatment of the fused protein with cyanogen bromide gives a biol. active VIP analog (in which the C-terminal amino acid residue is not Met but a homoserine or homoserine lactone residue derived from Met).

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:435895 CAPLUS
DN 113:35895
TI Interleukin-1 derivatives that do not induce prostaglandin E2 synthesis, and their recombinant preparation
IN Yamayoshi, Michiko; Kawashima, Hitoshi; Yamagishi, Junichi; Kotani, Hirotada; Furuta, Ryuji; Fukui, Toshikazu
PA Dainippon Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 327360	A2	19890809	EP 1989-301007	19890202
	EP 327360	A3	19900502		
	EP 327360	B1	19940706		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 01199998	A2	19890811	JP 1988-24613	19880203
	JP 2698976	B2	19980119		
	ES 2059717	T3	19941116	ES 1989-301007	19890202
PRAI	JP 1988-24613	A	19880203		

OS MARPAT 113:35895
AB Novel derivs. of human interleukin 1 (IL-1; α- or β-type) lacking undesirable side-effect of inducing prostaglandin E2 synthesis are prepared by **expressing** their genes in **microorganism**. The derivs. are formed by substitution and, optionally, deletion of N- and C-terminal amino acids of the wild-type IL-1. Polypeptide TN-55, a derivative of IL-1, was manufactured by Escherichia coli transformed with **expression** plasmid pHTN55. Polypeptide TN-55(141) having 14 N-terminal and 4 C-terminal amino acids deleted as well as **polypeptide** TN-55Asp having 36-**Asn** substituted with **Asp** were also manufactured and purified. The capacity of TN-55 to activate mouse thymus cells and to inducing prostaglandin E2 production by human osteosarcoma MG-63 cells were also evaluated.